LPCN Lipocine Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LPCN

Price (delayed)

$4.81

Market cap

$25.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.1

Enterprise value

$20.8M

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN ...

Highlights
The gross profit has grown by 7% since the previous quarter
LPCN's revenue is up by 7% since the previous quarter
The quick ratio has plunged by 57% YoY and by 21% from the previous quarter
LPCN's net income has shrunk by 52% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.lipocine.com/
Peers: JAZZ CORT MDWD TBPH

Key stats

What are the main financial stats of LPCN
Market
Shares outstanding
5.32M
Market cap
$25.57M
Enterprise value
$20.8M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.26
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
-$2.85M
EBIT
-$16.35M
EBITDA
-$16.32M
Free cash flow
-$11.88M
Per share
EPS
-$3.1
Free cash flow per share
-$2.25
Book value per share
$3.83
Revenue per share
-$0.54
TBVPS
$4.36
Balance sheet
Total assets
$23M
Total liabilities
$2.63M
Debt
$0
Equity
$20.37M
Working capital
$20.23M
Liquidity
Debt to equity
0
Current ratio
8.69
Quick ratio
8.37
Net debt/EBITDA
0.29
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-58.3%
Return on equity
-63.3%
Return on invested capital
-76.9%
Return on capital employed
-80.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LPCN stock price

How has the Lipocine stock price performed over time
Intraday
5.71%
1 week
-8.73%
1 month
-6.78%
1 year
-93.84%
YTD
72.4%
QTD
-7.5%

Financial performance

How have Lipocine's revenue and profit performed over time
Revenue
-$2.85M
Gross profit
-$2.85M
Operating income
-$17.93M
Net income
-$16.35M
Gross margin
N/A
Net margin
N/A
LPCN's net income has shrunk by 52% YoY
The company's operating income fell by 48% YoY
The gross profit has grown by 7% since the previous quarter
LPCN's revenue is up by 7% since the previous quarter

Growth

What is Lipocine's growth rate over time

Valuation

What is Lipocine stock price valuation
P/E
N/A
P/B
1.26
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Lipocine's EPS has shrunk by 50% YoY
The P/B is 58% less than the 5-year quarterly average of 3.0 but 58% more than the last 4 quarters average of 0.8
Lipocine's equity has decreased by 43% YoY and by 9% QoQ
LPCN's revenue is up by 7% since the previous quarter

Efficiency

How efficient is Lipocine business performance
The ROIC has plunged by 157% YoY and by 21% from the previous quarter
Lipocine's ROE has plunged by 129% YoY and by 15% from the previous quarter
LPCN's ROA has dropped by 126% year-on-year and by 13% since the previous quarter

Dividends

What is LPCN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LPCN.

Financial health

How did Lipocine financials performed over time
The current ratio has plunged by 57% YoY and by 21% from the previous quarter
The quick ratio has plunged by 57% YoY and by 21% from the previous quarter
LPCN's debt is 100% smaller than its equity
Lipocine's equity has decreased by 43% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.